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Available online 18 March 2016Background:With continued increase in the useofmechanical circulatory support, the incidence of device thrombus
remains a challenge. This study is a retrospective analysis of data at a single center to assess the safety and
efﬁcacy of thrombolytic use in durable mechanical assist devices.
Methods: Data was analyzed retrospectively from 154 patients who underwent left ventricular assist device
(LVAD) implantation from 1/1/2005 to 6/30/2014. The HMII device was implanted in 131 patients while 23 re-
ceived the HVAD. LVAD thrombus was diagnosed when lactate dehydrogenase levels exceeded 1000 units/l ac-
companied by clinical signs of hemolysis and heart failure, echocardiographic data and surges in pump power.
TPA (tissue plasminogen activator) protocol consisted of a 5 mg intravenous bolus followed by 3 mg/h infusion
in normal saline for 10 h. If symptoms persisted another cycle of TPA at 1 mg/h was continued up to 48 h.
Results: The TPA group had a 70% success rate. Success was deﬁned as complete resolution of hemolysis and clin-
ical symptoms with no requirement for LVAD exchange at 30 days. 95% survival was noted at 30 days and 90%
were free of a hemorrhagic stroke in the TPA group. The rates of hemorrhagic strokes in the TPA group and
the control group were not different (OR = 0.92).
Conclusion: The TPA protocol described here was successful consistently. Though this study is limited by its size
and retrospective nature it leads theway for larger studies to generatemore robust comparisons between differ-
ent types of mechanical assist devices as well as the tailored use of thrombolytics in this patient population.
© 2016 TheAuthors. Published by Elsevier Ireland Ltd. This is an openaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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CF pumps1. Background
Left ventricular assist devices (LVADs) have rapidly evolved as a
standard therapy for end stage heart failure either as bridge to trans-
plant (BTT) or as destination therapy (DT). The continuous-ﬂow
LVADS are smaller, less audible and more durable than the older pulsa-
tile pumps. The smaller size allows placement in patients with a smaller
body habitus [1]. With the extension of life and the more frequent use
of these devices, complications have also evolved in this population of
patients. Of these, bleeding and thrombosis have been the two major
challenges.
The HeartWare HVAD (centrifugal pump) and the HeartMate II
(axial-ﬂow) provide unloading of the left ventricle throughout the car-
diac cycle. This property leads to low pulse pressures and predisposition
to arteriovenous malformations in the gastrointestinal tract contribut-
ing to bleeding. Bleeding is one of the most common adverse events in
the ﬁrst month after implantation [2]. Additionally the shear forces
generated by these pumps accentuate the bleeding risk due to acquiredrtment of Medicine, Texas Tech
.
land Ltd. This is an open access articlvon Willebrand disease which is known to resolve after device explant
[2]. Passive hepatic congestion secondary to biventricular failure can
also predispose these individuals to increased bleeding complications.
Thrombus formation is the other complication that affects the
mechanical circulatory support population. Mechanical causes of
thrombosis include post-surgical ventricular debris, emboli secondary
to clots in the left atrial appendage and endocardial surface of the LV
as well as inﬂow cannula malposition [3]. Inadequate anti-coagulation
or anti-platelet therapy can contribute to thrombus formation. Interac-
tion of prosthetic material with blood, leads to signiﬁcant prolongation
of hematologic, inﬂammatory, or immunologic responses. Prolonged ac-
tivation of endothelial and coagulation systems after continuous ﬂow-
VAD implantation also seem to contribute to observed thrombosis.
Intercellular adhesion molecules, E-selectin, tissue factor and D-dimer
have all been shown to be up regulated status post-implantation [4,5].
Both HeartWare (HVAD) and HeartMate II (HMII) patients are
susceptible to thrombosis. Increasing incidence of pump thrombosis
has been well documented in literature [6–8]. Pump thrombosis can
cause life-threatening device malfunction and embolic strokes. Patients
with end-stage heart failure also tend to be in a pro-inﬂammatory state
which can promote thrombosis. Multiple mechanisms appear to con-
tribute to pump thrombosis [3–8].
Pump thrombosis is typically diagnosed by combination of increas-
ing lactate dehydrogenase (LDH)/plasma free hemoglobin, lowe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the left ventricle, pump power surges and sustained power elevations
[3]. Imaging modalities, such as CT and echocardiogram, are often
used to help identify thrombosis [9,10]. The efﬁciency of these modali-
ties to visualize the interior aspect of the pump is limited hence the en-
tire clinical picture needs to be used to arrive at the diagnosis. There is
limited data on the best therapy for pump thrombosis at present. Rec-
ommendations for management vary widely ranging from medical
management to catheter-directed thrombolysis and/or pump exchange
as the ﬁrst option [7–20].
The incidence of device thrombosis has been estimated as 2–13% in
adult continuous-ﬂow devices [3,6,8,21,22]. Prevention of thrombosis
would be the most ideal strategy, which seems far away in the present
day. The optimal doses of antiplatelet and anticoagulation treatments
are still undeﬁned due to lack of well-designed/controlled clinical trials.
Despite a fairly rigid regimen of anticoagulation and antiplatelet mea-
sures, pump thrombosis still occurs and has devastating consequences
[23–27]. In addition to the existing routinely used regimens, other anti-
coagulants/antiplatelet agents reported in the literature include
dipyridamole, pentoxifylline, dextran, and ﬂuindione [28–31].
Several etiologies for pump thrombosis, and the dilemma facedwith
treatment options, make this an important area of ongoing research
[6,8,22,32]. Though much knowledge has been gained in the ﬁeld of
anticoagulation, it is still difﬁcult to pinpoint the few factors that predis-
pose the patient to a device thrombus. Hence, the deﬁnition of a univer-
sal robust anticoagulation protocol still remains ambiguous.
As the standard of care in most centers is LVAD exchange which is a
procedure associated with a highmortality andmorbidity, a trial of TPA
thrombolysis may be appropriate prior to such a major surgical under-
taking in the absence of any contraindications. This retrospective
study therefore seeks to examine results of thrombolytic treatment
administered peripherally for LVAD thrombosis in both HVAD and
HMII patients at a single center. The speciﬁc aims are 1) to determine
if device thrombosis can be successfully treated with tissue plasmino-
gen activator (TPA) protocol used in this center 2) to assess complica-
tions associated with TPA treatment.
2. Methods
This retrospective studywas approved by Institutional ReviewBoard
Spokane (IRB#1942) in Spokane, Washington. A retrospective chart re-
viewwas performed on patients who had either received a HeartMate II
LVAD [Thoratec Corp., Pleasanton, CA] or a HeartWare HVAD LVAD
[HeartWare Inc., Framingham,MA] for BTT or DT during the time period
of January 1st, 2005 to June 30th, 2014. Patients who did not survive
implant or received biventricular assist devices were excluded from
the analyses. The sample included both men and women, who were
18 years or older. Patients included in this analysis were hemodynami-
cally stable and underwent VAD exchange if they failed TPA treatment.
The anticoagulation protocol consisted of aspirin and coumadin as per
manufacturer's recommendations (target INR of 1.8 to 2.5 for HMII
and 2.0 to 3.0 for HVAD). On admission PT/INR, PTT, CBC, complete
metabolic panel, ﬁbrinogen and a thromboelastogram with platelet
mapping were obtained. A 2-D echocardiogram was also performed
on admission.
2.1. Patient population and characteristics
Patient demographics collected included gender, age at LVAD
implant, Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) proﬁle, indication for LVAD (BTT or DT), type of
LVAD and history of comorbidities such as ischemic cardiomyopathy,
hypertension, diabetes mellitus, peripheral vascular disease, tobacco
use, anemia or hypercoagulable syndrome.
Analyses of factors that predispose to LVAD thrombus included
length of VAD support, type of LVAD, history of peripheral vasculardisease (PVD), tobacco use, hypercoagulable state, anemia, hyperten-
sion and diabetes. Additional outcome variables were evaluated for pa-
tients who met the criteria for suspected LVAD thrombus, including
time to thrombus event, time to the second thrombus event (if applica-
ble), use of TPA, and LVAD exchange. Any differences in time to occur-
rence of suspected thrombus between the two LVAD types were also
evaluated. Adverse events such as renal failure, hemorrhagic CVA, and
right ventricular failure were evaluated in conjunctionwith TPA admin-
istration. Success with TPA administration was deﬁned as resolution of
hemolysis and no indication for LVAD exchange for 30 days.
3. Study design
Retrospective analyses were performed on patient charts after
IRB approval. The study population comprised of 154 patients
who underwent left ventricular assist device (LVAD) implantation
(131-HeartMate II and 23-HVAD) from 1/1/2005 to 6/30/2014. They
were divided into four groups — HM II with device thrombosis, HVAD
with device thrombosis, HM II with no device thrombosis, and HVAD
with no device thrombosis (Fig. 1A). A total of 24 patients were
diagnosedwith LVAD thrombus. Of these, 20 patients received TPA infu-
sions, 3 underwent LVAD exchange and 1 patientwas placed on heparin
and Plavix (Fig. 1B). Patients who were hemodynamically unstable
underwent LVAD exchange.
3.1. Diagnosis of thrombosis
Occurrence of LVAD thrombus was suspected with elevated LDH,
hematuria, elevated quantitative plasma free hemoglobin. Diagnosis
of LVAD thrombus was made when lactate dehydrogenase levels
exceeded 1000 units/l in addition to clinical signs of hemolysis and
heart failure and echocardiographic ﬁndings listed above. The plasma
free hemoglobin was monitored concomitantly but absolute cut off
values were not used to make a diagnosis due to high variability in the
assay values at this center. A cannulaﬂowvelocity of N2m/s by echocar-
diography with more frequent opening of the aortic valve than at base-
line in the context of increasing left ventricular internal dimension in
diastole (LVIDd) without any manual speed changes was considered
suggestive of a thrombus.
3.2. TPA protocol
TPA protocol typically consisted of a 5 mg intravenous bolus
followed by 3 mg/h infusion in normal saline for 10 h. In cases where
thrombus persisted as deﬁned by laboratory data and clinical signs an-
other cycle of TPA at 1 mg/h was continued up to 48 h. The total TPA
dose never exceeded a maximum limit of 100 mg. All TPA infusions
were performed via a peripherally inserted central intravenous line in
the cardiac intensive care unit.
3.3. Statistical analysis
Descriptive statistics (mean, median, and standard deviation) were
used to characterize the patient population, including baseline charac-
teristics, thrombosis rates between devices, and results of TPA treat-
ment and associated events. Success rates for TPA treatment were
computed. Inferential statistics were used to test for independence
between groups. A t-test was used to compare means for age and
time to LVAD thrombosis, with conﬁdence intervals denoted. The
Chi-square test or Fischer's exact test (for small sample size) was used
to test for independence between categorical variables. The Cramer's
V test was utilized to calculate correlation. Odds ratios (OR) were
calculated for categorical data. Statistical tests were performed using
SPSS and Excel. Results were considered signiﬁcant if p b 0.05.
Fig. 1. A shows the distribution of the two types of continuous ﬂow pumps in the study population. B shows survival at 30 days.
Table 1
Baseline characteristics of study population.
All study subjects
(n = 154)
Patients without
an LVAD
Patients with an
LVAD
Thrombus event
(n = 130)
Thrombus event
(n = 24)
Mean age at implant 55.8 55.6 56.9
Gender 33 (21.4) F, 121
(78.6) M
27 (20.8) F, 103
(79.2) M
6 (25) F, 18 (75)
M
Ischemic CM 85 (55.2) 71 (54.6) 14 (58.3)
Non-ischemic CM 69 (44.8) 59 (45.4) 10 (41.7)
HTN 65 (42.2) 54 (41.5} 11 (45.8)
51N. Nair et al. / IJC Heart & Vasculature 11 (2016) 49–544. Results
4.1. Characteristics of study population
Table 1 outlines the baseline characteristics of the patients. The
study population had 21% females and 78.6% males. Ischemic and non-
ischemic cardiomyopathies were equally represented. Hypertension
and diabetes were noted in 43% and 35% of the study subjects respec-
tively. Only 8.4% of the subjects had peripheral vascular disease. History
of tobacco usewas noted in 55% of the study population. A higher num-
ber of HM II LVADs were placed as compared to HVADs (85.1% versus
14.9%) in the period studied from 2005 to 2014. Approximately one
tenth of the patients were in INTERMACS class 1.OM 54 (35.1) 44 (33.8) 10 (41.7)
Peripheral vascular
disease
13 (8.4) 10 (7.7) 3 (12.5)
History of tobacco use 85 (55.2) 69 (53.1) 16 (66.7)
HMII 131 (85.1) 111 (85.4) 20 (83.3)
HVAD 23 (14.9) 19 (14.6) 4 (16.7)
Length of pump
support (days)
550 + 475 526 + 494 682 + 330
BTT 110 (71.4) 94 (72.3) 16 (66.7)
DT 44(28.6) 36 (27.7) 8 (33.3)
Pump exchange 14(9.1) 4(3.1) 10 (41.7)
GI bleed 40 (26) 33 (25.4) 7 (29.2)
Driveline infection 24 (15.6) 16 (12.3) 8 (33.3)
INTERMACS Proﬁle 1 15(9.7) 15 (11.5) 0
INTERMACS Proﬁle 2 54 (35.1) 50 (38.5) 4 (16.7)
INTERMACS Proﬁle 3 40 (26.0) 31 (23.8) 9 (37.5)
INTERMACS Proﬁle 4 30 (19.5) 22 (16.9) 8 (33.3)
INTERMACS Proﬁle 5 8 (51.9} 6 (4.6) 2 (8.3)
INTERMACS Proﬁle 6 6 (39) 5 (3.8) 1 (4.2)
INTERMACS Proﬁle 7 1(0.6) 1 (0.6) 0
F—Female; M—Male.4.2. Factors inﬂuencing VAD thrombus formation
Table 2 outlines factors that could contribute to pump thrombus.
However there was no signiﬁcance between the non-thrombus
group and thrombus group patient demographics with respect to age
(p = 0.637), gender (p = 0.64), history of ischemic cardiomyopathy
(p = 0.73), hypertension (p = 0.7), diabetes mellitus (p = 0.46),
peripheral vascular disease (p=0.44), tobacco use (p=0.22), and ane-
mia (p = 0.11). Patients in the thrombus group were found to have a
history for hypercoagulable syndrome with intermediate association
strength (p b 0.000, V = 0.328). There were no signiﬁcant differences
between the non-thrombus group and thrombus group in operative
characteristics with respect to LVAD indication for BTT or DT (p = 0.57)
or LVAD type (p = 0.80). The INTERMACS proﬁle was not signiﬁcant in
either group (p = 0.09). Patients included had INR within the recom-
mended therapeutic range on presentation.
Table 2
Analysis of factors contributing to VAD thrombus.
(−) Thrombus
N = 130
(+) Thrombus
N = 24
p
value
Correlation
coefﬁcientCharacteristics
Age (years) 55.60% 56.40% 0.637 0.037
Gender (female) 27 6 0.266
HMII 84.70% 15.30% 0.796 0.021
HVAD 82.60% 17.40%
History of PVD 7.70% 12.50% 0.436 0.063
History of Tobacco Use 53.10% 66.70% 0.219 0.99
History of Hypercoagulable
Syndrome
0.00% 12.50% 0.000 0.328
History of Anemia 10.00% 0.00% 0.105 0.13
History of Hypertension 54 (41.5%) 11 (45.8%) 0.7 0.025
History of Diabetes 44 (33.8%) 10 (41.7%) 0.46 0.06
Table 4
Outcomes with TPA protocol and LVAD exchange.
1st thrombus
(n = 20)
2nd thrombus
(n = 4)
TPA protocol 83.3% 57.1%
Free of hemorrhagic stroke following TPA 90.0% 100.0%
Alive at 30 days post-TPA 95.0% 50.0%
Alive at 1 year post-TPA or ongoing 75% 25%
1st thrombus
(n = 3)
2nd thrombus
(n = 3)
VAD exchange 12.5% 42.9%
Free of hemorrhagic stroke following
VAD exchange 100.0% 100.0%
Alive at 30 days post-surgery 100.0% 100.0%
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The average time to ﬁrst thrombus event was 394 days (CI 256.6–
531.3). The average time to ﬁrst thrombus event for HMII LVAD patients
was 357 days (CI 209.5–503.7). The average time to the ﬁrst thrombus
event for HVAD patients was 581 days (CI 81.6–1079.9). The average
time from the ﬁrst thrombus event to the second thrombus event was
314.7 days (CI 81.4, 548). No statistical signiﬁcance was noted (Table 3).
4.4. Patient outcome variables in the thrombus versus No thrombus groups
Patient outcome variables showed no signiﬁcant differences be-
tween the non-thrombus group and thrombus group in relation to
length of LVAD support (p = 0.06), occurrence of GI bleed (p = 0.70),
driveline infection (non-thrombus group vs. thrombus group, at any
time, p = 0.10), hemorrhagic CVA (p = 0.72), renal failure (p = 0.69),
or right ventricular failure (p = 0.24). Analysis of the study groups
showed no statistically signiﬁcant differences in driveline infections or
GI bleeding pre- and post-thrombus formation. Approximately 17%
(n=4) of the patients who experienced an LVAD thrombus had a drive-
line infection prior to the thrombus event, which was not signiﬁcant in
comparison to the non-thrombus patient group (p = 0.35).
4.5. Outcomes and adverse events with TPA protocol versus LVAD exchange
Tables 4 and 5 show outcomes and adverse events with TPA treat-
ment versus LVAD exchange. Approximately 83.3% (n= 20) of patients
received TPA. 1 patient did not survive until 30 days post-TPA adminis-
tration. Of the 20 patients who received TPA for a ﬁrst thrombus event,
10% experienced a related hemorrhagic CVA, 20% experienced renal fail-
ure, and 5% experienced right ventricular failure following TPA adminis-
tration or throughout the remainder of the hospital admission. For those
patientswho received TPA for a ﬁrst thrombus event, the corresponding
non-thrombus group was more likely to have right ventricular failure
(OR: 3.1). Renal failure did not increase in patients who experienced
an LVAD thrombus (OR: 0.91). Hemorrhagic CVA did not increase in pa-
tients who experienced an LVAD thrombus (OR: 0.92). All the 4 HVAD
patients who experienced a ﬁrst thrombus event received TPA and
were treated successfully. Of the 16 HMII LVAD patients who experi-
enced a ﬁrst thrombus event and received TPA, 63% were treatedTable 3
Average time to diagnosis of thrombus.
Time to 1st LVAD thrombus
(HMII: n = 20, HVAD: n = 4)
Time from 1st to 2nd thrombus
(HMII: n = 5, HVAD: n = 2)
HMII & HVAD
(n = 24) 394 ± 326 315 ± 554
HMII (n = 20) 357 ± 315 382 ± 660
HVAD (n = 4) 581 ± 360 146 ± 124
p = nssuccessfully. Sample size was too small for appropriate statistical analy-
sis. Only 12.5% (n = 3) of patients received an LVAD exchange for the
ﬁrst suspected thrombus event, with all 3 patients surviving post-
30 days of surgery. Of the 3 patients who received an LVAD exchange,
0% experienced hemorrhagic CVA, renal failure or right ventricular fail-
ure immediately following LVAD exchanges or throughout the remain-
der of the hospital stay. Sample sizewas too small for statistical analysis.
4.2% (n = 1) of patients did not receive either TPA or LVAD exchange,
but instead received a combination of heparin and clopidogrel.
Of the 29.2% (n = 7) of patients who experienced a second
suspected thrombus event, 4 received TPA and 3 received an LVAD
exchange. From the group treated with TPA, 1 of the 4 experienced
right ventricular failure. None experienced hemorrhagic CVA or renal
failure following TPA administration or throughout the remainder of
the hospital admission. 2 patients did not survive until 30 days post-
TPA administration. From the group treated with LVAD exchange, 1 of
3 experienced right ventricular failure. None experienced hemorrhagic
CVA or renal failure following LVAD exchange or throughout the
remainder of the hospital admission.5. Discussion
This study is different from earlier investigations in that a single de-
ﬁned protocol was used to treat LVAD thrombosis Though the analyses
was retrospective, the study showed a 95% survival rate with TPA at
30 days and 75% at 1 year for patients treated with TPA at the ﬁrst inci-
dence of pump thrombus. The number of patients treated at the second
instance of pump thrombus was small, but a drop in survival was noted
at 30 days at 50% and only 25% at 1 year. The sample sizeswere too small
to perform any meaningful statistical analyses. In our limited experi-
ence, TPA appeared to be the ﬁrst choice instead of a pump exchange
in hemodynamically stable individuals. A notable aspect of this protocol
is that the adverse events were comparable in the thrombus and
non-thrombus groups. The odds ratio points to a larger likelihood of
developing right ventricular failure in the non-thrombus groups.
Some of the challenges in assessing VAD thrombus problems are the
lack of adequate deﬁnition of the number of thrombi that are true ver-
sus suspected, and the lack of a uniﬁed anticoagulation/antiplatelet reg-
imen. Additionally it is unclear if the length of pump support factors into
the equation. The studies by Boyle et al. and Slaughter et al. [24,25]
showed that patients can be maintained at lower INR and without the
heparin bridging for optimal management.
In a recent report by Najjar et al. medical management in general
showed a 50% success rate and a 63% success rate with TPA treatment
in particular [3]. Schlendorf et al. found a 37.5% success with thrombo-
lytic therapy [16]. Our study shows a success rate of 70% with TPA
including both HMII and HVAD patients. It should be noted that
our study included a majority of HMII pumps and lower number of
HVADS as compared to the by Najjar et al. which focused on the
Table 5
Adverse event proﬁle in study population.
(−) Thrombus TPA LVAD exchange
No thrombus (n = 130) 1st thrombus event (n = 20) 2nd thrombus event (n = 4) 1st thrombus (n = 3) 2nd thrombus (n = 3)
Hemorrhagic stroke 9.2% 10.0% 0.0% 0.0% 0.0%
Renal failure 18.0% 20.0% 0.0% 0.0% 0.0%
RV failure 14.0% 5.0% 25.0% 0.0% 33.3%
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therapy patients also in the analysis.
The hemorrhagic CVA noted in 10% of patients which included those
with bothHM II andHVAD. Though reports of associations between ear-
lier bleeding events followed by incidence of pump thrombus exist in
the literature [33,34] a signiﬁcant correlation between GI bleeds and
pump thrombus events was not found in this retrospective analysis.
Patients with a history of hyper-coagulation syndromes were
signiﬁcantly predisposed to LVAD thrombosis. This is an area where
rigorous investigation is required to deﬁne levels of anticoagulation.
Anticoagulation requirements may be very different in these patients.
Besides, hypercoagulability in the setting of heart failure may be more
accentuated due to chronic inﬂammation and up regulation of coagula-
tion factors in heart failure [35,36]. Systematic studies on the pathogen-
esis of heart failure will shed light on subsets of patients whomay have
a higher risk for hypercoagulation in the context of up regulation of
markers of inﬂammation, ﬁbrosis, and coagulation. Such tailored risk
assessment may be helpful in high risk populations. Better risk stratiﬁ-
cation will help in better prognostication and management. Genotype
driven anticoagulation regimens could be another useful approach in
this population [37].
In this single center protocol thrombolytic treatment was used prior
to initiating a VAD exchange if the patient had no contraindications. All
patientswere evaluated carefully for risk versus beneﬁt before initiating
a treatment protocol. A protocol for triaging patients with a suspected
thrombus is shown in Fig. 2 which differs from the algorithm put forth
by the ISHLT working group [26] in that the protocol presented here
focuses on thrombolytics. The algorithm shown here is intended to
help develop further investigations on these lines in larger studies
using different types of mechanical pumps to gain further insight into
optimal treatment options and outcome strategies.Fig. 2. A suggested algorithm for use of thrombolytic th6. Limitations
This is a small retrospective analysis which makes it difﬁcult to per-
formmeaningful statistics especially in terms of long term outcomes in
comparisonwith LVAD exchange. The dilemma in deﬁnitively diagnosing
a true thrombus versus signs and symptoms suggestive of a thrombus still
remains. The data on the second thrombus event is too small for any
comparison. The LVAD exchange group is also very small for any head
to head comparison with the thrombolytic therapy group.
Being a retrospective study no log ﬁle analysis was done on the
HVAD patients as this technique was not universally available at the
time the patients were implanted. The hypercoagulable state noted in
the study patientswere only by history. No datawas available regarding
the types/etiology of the hypercoagulability in these patients. The per-
centage of patients in atrial ﬁbrillation at the time of presentation
could not be deciphered as this datawasmissing from the data set avail-
able for the analysis.
7. Conclusions
This was a retrospective study consisting of patient record analyses
of 154 patientswhounderwent left ventricular assist device (LVAD) im-
plantation (131-HM II and 23-HVAD) from 1/1/2005 to 6/30/2014. A
single TPA protocol was used in this study population. The TPA protocol
patients showed an overall 70% success including the HMII and HVAD
pumps and the survival at 30 days post-thrombolytic therapy was
95%. At one year the survival was 75%. Success with VAD exchange
was 100%. Survival at 30 days and 1 yearwas also a 100% in the VAD ex-
change population. The patientswhounderwent VAD exchange directly
had contraindications to thrombolytic treatment. However the VAD ex-
change group was very small to perform any meaningful statisticalerapy in the mechanical assist device population.
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VAD exchange for a second thrombus event because these patients
were poor surgical candidates. As the number of patients in the second
thrombus group was small no statistical analyses was performed.
Though this is a small retrospective study the TPA protocol presented
here, when used appropriately appears to yield acceptable preliminary
results in terms of safety and survival. The protocol needs validation in
large multicenter trials for further deﬁnition and optimization in differ-
ent patient subsets and varied anticoagulation patterns.
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